Processa Pharmaceuticals Inc (PCSA)
1.06
-0.01
(-0.93%)
USD |
NASDAQ |
Nov 14, 16:00
1.06
0.00 (0.00%)
After-Hours: 17:48
Processa Pharmaceuticals Enterprise Value: -2.086M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -2.086M |
| November 12, 2024 | -2.086M |
| November 11, 2024 | -1.988M |
| November 08, 2024 | -1.988M |
| November 07, 2024 | -1.826M |
| November 06, 2024 | -1.923M |
| November 05, 2024 | -1.988M |
| November 04, 2024 | -1.956M |
| November 01, 2024 | -1.826M |
| October 31, 2024 | -1.809M |
| October 30, 2024 | -1.239M |
| October 29, 2024 | -1.174M |
| October 28, 2024 | -1.174M |
| October 25, 2024 | -1.305M |
| October 24, 2024 | -1.337M |
| October 23, 2024 | -1.174M |
| October 22, 2024 | -1.207M |
| October 21, 2024 | -0.9789M |
| October 18, 2024 | -1.012M |
| October 17, 2024 | -1.272M |
| October 16, 2024 | -1.239M |
| October 15, 2024 | -1.533M |
| October 14, 2024 | -1.533M |
| October 11, 2024 | -1.305M |
| October 10, 2024 | -1.467M |
| Date | Value |
|---|---|
| October 09, 2024 | -1.435M |
| October 08, 2024 | -1.467M |
| October 07, 2024 | -1.533M |
| October 04, 2024 | -1.695M |
| October 03, 2024 | -1.305M |
| October 02, 2024 | -1.239M |
| October 01, 2024 | -1.243M |
| September 30, 2024 | -1.109M |
| September 27, 2024 | -1.109M |
| September 26, 2024 | -1.369M |
| September 25, 2024 | -1.239M |
| September 24, 2024 | -1.213M |
| September 23, 2024 | -1.143M |
| September 20, 2024 | -1.142M |
| September 19, 2024 | -1.109M |
| September 18, 2024 | -0.9463M |
| September 17, 2024 | -0.9463M |
| September 16, 2024 | -0.8486M |
| September 13, 2024 | -1.207M |
| September 12, 2024 | -1.207M |
| September 11, 2024 | -1.305M |
| September 10, 2024 | -1.305M |
| September 09, 2024 | -1.239M |
| September 06, 2024 | -1.402M |
| September 05, 2024 | -1.273M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-4.690M
Minimum
May 31 2024
188.70M
Maximum
Mar 18 2021
35.55M
Average
22.98M
Median
Sep 20 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
| Oragenics Inc | 2.142M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.010M |
| Total Expenses (Quarterly) | 3.082M |
| EPS Diluted (Quarterly) | -1.01 |
| Earnings Yield | -509.4% |
| Normalized Earnings Yield | -13303.63 |